Highly Rated, Highly Effective

For nearly 50 years, The Meadows has led in trauma, addiction, and mental health treatment. We combine evidence-based therapies, modern neuroscience, and a whole-person approach to help patients heal and thrive. Our outcomes, independently validated by Vista Research Group, track patients across all programs, from intake through treatment and up to one year post-treatment, showing how expertise, individualized care, and community create lasting, measurable results.

We focus on patient-reported well-being, engagement, satisfaction, quality of life, progress on personal goals, symptom reduction, and abstinence to capture the full impact of lasting recovery and life transformation.

The Power of Feeling Heard and Supported


The power of feeling seen, heard, and supported is evident in our strong patient satisfaction rates and Net Promoter Score. Individual and group therapy play a central role in our approach, finding connection, addressing trauma, and fostering resilience.

Patient Satisfaction

All Inpatient Programs

91% of patients feel satisfied with the treatment they are receiving.

All Outpatient & VIOP Programs

86% of patients feel satisfied with the treatment they are receiving.

Recovery isn’t linear, and our continuum of care supports patients wherever they are, with healing that fits.

For inpatient programs, longer stays and high completion rates, and for outpatient programs, consistent attendance, reflect active engagement and commitment to treatment.

Outpatient Attendance rate

Inpatient Treatment Completion rate

Inpatient Average Length of Stay

Recovery that Lasts

The measurable impact of personalized, trauma-focused care

Post-treatment abstinence rates above industry average

Patients with moderate to severe substance use disorders maintain abstinence long after treatment. Percentages reflect the rates of patients who were reachable.

Because addiction is a chronic disease, Vista defines success for substance use disorder patients as maintaining at least 30 days of abstinence.

1 Month

72% Abstinent since treatment


6 Months

78% Abstinent last 30 days


12 Months

88% Abstinent last 30 days


We use Vista Research Group for independent, third-party research that measures the effectiveness of our programs. Their platform provides real-time patient monitoring and long-term follow-up data, allowing us to evaluate outcomes with transparency and accuracy. These insights help us continuously improve care, demonstrate effectiveness, and build trust with patients, loved ones, providers, and payers.

About This Data:

About This Data

Patient Satisfaction

N = 20,089 monitoring surveys through 2024; scores below take an average of all surveys.

All Inpatient

  • 91% of patients feel satisfied with the treatment they are receiving.

All Outpatient & VIOP

  • 86% of patients feel satisfied with the treatment they are receiving.

All Meadows Programs – Post Discharge Satisfactions

Among patients who submitted surveys between 8/19/2022- 12/31/2024.

  • 1 mo post (n = 1,088): 86% somewhat or very satisfied
  • 6 mos post (n = 745): 86% somewhat or very satisfied
  • 12 mos post (n = 426): 85% somewhat or very satisfied

Improved Quality of Life

All Meadows Programs

Overall Feeling Post-Treatment

1 Month Post-Treatment

Among 1,682 patients discharged between 8/19/2022-12/31/2024, 65% were reachable at 1 month post-treatment (n = 1,093).

  • of patients who were reachable, 91% (n = 992) were feeling excellent, good, or fair

6 Months Post-Treatment

Among 1,315 patients discharged between 8/19/2022- 7/31/2024, 57% were reachable at 6 months (n = 749).

  • Of patients who were reachable, 89% (n = 670) were feeling excellent, good, or fair

12 Months Post-Treatment

Among 840 patients discharged between 8/19/2022- 1/31/2024, 51% were reachable at 12 months (n = 428).

  • Of patients who were reachable, 92% (n = 395) were feeling excellent, good, or fair

Increased from 94% at start of treatment to 97% one year after discharge

This is a 3.19% increase in patients living in stable housing.

Living in Stable Housing (n = 421 patients):

  • Increased from 94% at start of treatment to 97% one year after discharge
    • This is a 3.19% increase in patients living in stable housing.

Good Relationship with Closest Family Members (n = 421 patients):

  • 69% reported excellent, good, or fair at start of treatment, increasing to 94% one year post-treatment.
    • This is a 36.23% increase in good relationship with closest family members.

Employment (n = 421 patients):

  • 73% reported working, going to school, or working in the home at the start of treatment, increasing to 77% one year post-treatment.
    • This is a 5.47% increase in employment

 


SUD Abstinence Rates

Of the 1,722 patients who were discharged from The Meadows on or before December 31, 2024, 52% reported having had at least 4 of the 11 DSM-5 symptoms of substance use disorder (SUD) in the year prior to entering treatment. Those who met the criteria for having at least a moderate SUD were asked about their drug and alcohol use on each of the follow-up surveys.

Because addiction is a chronic disease and relapse a common occurrence, Vista considers having been abstinent for at least the last 30 days to be a key measure of success for patients with substance use disorders.

1 Month Post-Treatment

Among 882 patients discharged between 8/19/2022-12/31/2024, 61% were reachable at 1 month (n = 538).

  • Of patients who were reachable, 72% were abstinent since treatment (n = 388)

6 Months Post-Treatment

Among 672 patients discharged between 8/19/2022- 7/31/2024, 53% were reachable at 6 months (n = 356).

  • Of patients who were reachable 6 months post treatment, a total of 78% were abstinent in the last 30 days
    • 60% (n = 215) were abstinent since treatment
    • 18% (n = 67) were abstinent the last 30 days

12 Months Post-Treatment

Among 410 patients discharged between 8/19/2022- 1/31/2024, 45% were reachable at 12 months (n = 184).

  • Of patients who were reachable 12 months post-treatment, a total of 88% were abstinent in the last 30 days
    • 53% (n = 98) were abstinent since treatment
    • 35% (n = 65) were abstinent the last 30 days

Depression Symptoms

All Meadows Programs – 2024 Progress During Treatment

n = 3,774

Depression (PHQ-9):

  • Patients reporting Moderate to Severe Depression symptoms decreased from 74% at intake to 26% at discharge.
    • This is a 64.86% decrease in depression symptoms reported.

Impact of Treatment on Lasting Symptom Reduction – Patients Reporting Moderate to Severe Depression (PHQ-9) Symptoms:

For patients discharged between 8/19/20222 – 12/31/24; Patient submitted surveys received by 1/31/25. 

  • Intake – 73% (n=1724)
  • Discharge – 27% (n=1486)
  • 1 month post-treatment – 23% (n=1087)
  • 6 months post-treatment  – 24% (n=745)
  • 12 months post-treatment – 28% (n=426)

 


Anxiety Symptoms

All Meadows Programs – 2024 Progress During Treatment

n = 3,774

Anxiety (GAD-7):

  • Patients reporting Moderate to Severe Anxiety symptoms decreased from 69% at intake to 25% at discharge.
    • This is a 63.76% decrease in anxiety symptoms reported.

Impact of Treatment on Lasting Symptom Reduction – Patients Reporting Moderate to Severe Anxiety (GAD-7) Symptoms:

For patients discharged between 8/19/20222 – 12/31/24; Patient submitted surveys received by 1/31/25. 

  • Intake – 68% (n=1724)
  • Discharge – 25% (n=1486)
  • 1 month post-treatment – 20% (n=1087)
  • 6 months post-treatment  – 20% (n=745)
  • 12 months post-treatment – 26% (n=426)

 


PTSD Symptoms

All Meadows Programs – 2024 Progress During Treatment

n = 3,774

PTSD (PCL-6):

  • Patients reporting PTSD symptoms decreased from 67% at intake to 31% at discharge.
    • This is a 53.73% decrease in PTSD symptoms reported.

Impact of Treatment on Lasting Symptom Reduction – Patients Reporting PTSD (PCL-6) Symptoms:

For patients discharged between 8/19/20222 – 12/31/24; Patient submitted surveys received by 1/31/25. 

  • Intake – 67% (n=1724)
  • Discharge – 32% (n=1486)
  • 1 month post-treatment – 25% (n=1087)
  • 6 months post-treatment  – 27% (n=745)
  • 12 months post-treatment – 28% (n=426)

 


Average Length of Stay

N = 3,750 patients discharged between 01/01/24-12/31/24

Inpatient Average Length-of-Stay

n = 1,199 for inpatient

  • 43 Days

For outpatient programs, this length-of-stay counts calendar days and does not account for days not in session.

Outpatient Average Length-of-Stay

n = 2,551 for outpatient

  • 64 Days

For outpatient programs, this length-of-stay counts calendar days and does not account for days not in session.

 

 

 


Found Therapy Helpful

All Meadows Programs

n = 3,423 patients surveyed in 2024.

Individual Therapy

  • 71% reported very or extremely helpful

Group Therapy

  • 78% reported very or extremely helpful

 


Treatment Completion

N = 3,750 patients discharged in 2024.

All Meadows Programs

  • 74% of patients across all Meadows programs completed all recommended treatment.

All Inpatient

  • Our inpatient programs have an 88% completion rate.

All Outpatient & VIOP

  • 73% of outpatient and viop patients complete all recommended treatment or are refeRred to a higher level of care.

 

 


Outpatient Attendance

N=2,479 outpatient patients were discharged in 2024.

Attendance Rate

  • Outpatient programs had a combined attendance rate of 86%.
    • In-Person Outpatient: 87%
    • Virtual Outpatient: 85%
    • Adolescent Outpatient: at 80%